New agents in development for breast cancer

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 1, 2007, Pages 68-74

  Gao, Xiao Ping ^a   Liu, Fang ^a  

^a Sichuan Institute of Chinese Materia Medica   (China)

Author keywords

Aromatase inhibitors; Breast cancer; Growth factor receptor antagonist; Selective estrogen receptor modulators

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BMS 554417; CANERTINIB; CP 654577; DOCETAXEL; DROLOXIFENE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GW 654652; IDOXIFENE; INDAZOLYLPYRIMIDINE; LAPATINIB; MONOCLONAL ANTIBODY; PERTUZUMAB; PLACEBO; PQ 401; PYRIMIDINE DERIVATIVE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN RECEPTOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; DRUG EFFICACY; ENDOMETRIUM CANCER; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; STROKE; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33846205915     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e328011e6a2     Document Type: Review

References (80)

1. Balselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpression human breast cancer xenografts. Cancer Res 1998; 58:2825-2831.
2. Willems A, Gauger K, Henrichs C. Antibody therapy for breast cancer. Anticancer Res 2005; 25:1483-1489.
3. Gee JM, Harper ME, Hutcheson IR, et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003; 144:5105-5117.
4. Ouchi KF, Yanagisawa M, Sekiguchi F, et al. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol 2006; 57:693-702. Erlotinib inhibits tumor growth in a range of human tumor xenograft models, including breast and colorectal cancer.
5. Ariazi EA, Ariazi JL, Codera F, et al. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006; 6:181-202. Estrogen receptor modulators and aromatase inhibitors continue to be valuable in the endocrine therapy of breast cancer.
6. Kudchadkar R, O'Regan RM. Aromatase inhibitor as adjuvant therapy for postmenopausal patients with early stage breast cancer. Cancer J Clin 2005; 55:145-163. Aromatase inhibitors are as good as tamoxifen, and are widely used as first-line therapies. Likewise, the aromatase inhibitors are as effective, and perhaps better in specific subsets of patients, than tamoxifen in the adjuvant treatment of early stage breast cancer in postmenopausal women.
7. Aaronson SA. Growth factors and cancer. Science 1991; 254:1146-1153.
8. Di Fiore PP, Pierce JH, Kraus MH, et al. erbB2-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987; 237:178-182.
9. Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995; 269:234-238.
10. Threadgill DW, Duugosz AA, Hansen LA, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995; 269:230-234.
11. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24:2786-2792.
12. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23:2534-2543.
13. Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Can Immunol Immunother 2006; 55:717-727.
14. Gordon MS, Matei D, Aghajanian C, et al. A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer 2006; 6:535-539.
15. Moulder SL, Yakes FM, Muthuswamy SK, et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61:8887-8895.
16. Winer E, Cobleigh M, Dickler M, et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2002; 76:5115a.
17. Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005; 11:5300-5309.
18. von Minckwitz G, Jonat W, Fasching P, et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 2005; 89:165-172.
19. Albain K, Elledge R, Gradishar WJ, et al. Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 2002; 76 (Suppl 1):A20.
20. Robertson JFR, Gutteridge E, Cheung KL, et al. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Proc Am Soc Clin Oncol 2003; 22:7.
21. Ciardiello F, Troiani T, Caputo F, et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006; 94:1604-1609.
22. Barbacci EG, Pustilnik LR, Rossi AM, et al. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. Cancer Res 2003; 63:4450-4459.
23. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1:85-94.
24. Mellinghoff IK, Tran C, Sawyers CL. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 2002; 62:5254-5259.
25. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315:971-979.
26. Helle SL. The insulin-like growth factor system in advanced breast cancer. Best Prac Res Clin Endocrinol Metab 2004; 18:67-79.
27. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000; 36:1224-1228.
28. Shimizu C, Hasegawa T, Tani Y, et al. Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 2004; 35:1537-1542.
29. Dupont J, Le Roith D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast. J Clin Pathol: Mol Pathol 2001; 54:149-154.
30. Sachdev D, Hartell JS, Lee AV, et al. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 2004; 279:5017-5024.
31. Carboni JM, Lee AV, Hadsell DL, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005; 65:3781-3787.
32. Knowlden JM, Hutcheson IR, Barrow D, et al. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005; 146:4609-4618.
33. Haluska P, Carboni JM, Loegering DA, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006; 66:362-371.
34. Gable KL, Maddux BA, Penaranda C, et al. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther 2006; 5:1079-1086. A new compound targeting insulin-like growth factor I receptor signaling, PQ401 (diaryl urea), which inhibits the proliferation of breast cancer cells in vitro and reduces the growth of breast cancer in vivo. It may therefore be developed as a promising agent different from other receptor signaling inhibitors in the treatment of breast cancer.
35. Dales JP, Garcia S, Bonnier P, et al. Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma. Ann Pathol 2003; 23:297-305.
36. Nakopoulou L, Stefanaki K, Panayotopoulou E, et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol 2002; 33:863-870.
37. Kim LS, Huang S, Lu W, et al. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 2004; 21:107-118.
38. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24:769-777.
39. Huh JI, Calvo A, Stafford J, et al. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and nonantiangiogenic mechanisms. Oncogene 2005; 24:790-800.
40. Massarweh S, Shou J, DiPietro M, et al. Targeting the epidermal growth factor receptor pathway improves the antitumor effect of tamoxifen and delays acquired resistance in a xenograft model of breast cancer. Breast Cancer Res Treat 2002; 76:S33.
41. Robertson J, Guttedridge E, Cheung K, et al. A phase II study of ZD1839 (Iressa) in tamoxifen-resistant ER-positive and endocrine-insensitive (ER-negative) breast cancer. Breast Cancer Res Treat 2002; 76:S96.
42. Winer EP, Cobleigh M, Dickler M, et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2002; 76:S115.
43. Xia WL, Mullin RJ, Keith BR, et al. Antitumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21:6255-6263.
44. Howard A, Burris III, Herbert I, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23:5305-5313.
45. Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 2004; 22:3006.
46. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
47. Borg A, Tandon AK, Sigurdsson H, et al. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50:4332-4337.
48. Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002; 71:67-75.
49. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1:85-94.
50. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000; 60:970-975.
51. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62:4645-4655.
52. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9:1546-1556.
53. Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005; 11:3369-3376.
54. Allen LF, Eiseman IA, Fry DW, et al. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment breast cancer. Semin Oncol 2003; 30:65-78.
55. Haluska P, Carboni JM, Loegering DA, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006; 66:362-371.
56. Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006; 103:7795-7800. This article provided a model of acquired resistance to lapatinib, an inhibitor of ErbB2 and ErbB1 tyrosine kinases, and the mechanism of acquired lapatinib resistance is related to the enhancement of estrogen receptor signaling.
57. Kuiper GGJM, Enmark E, Pelto-Huikko M, et al. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93:5925-5930.
58. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001; 29:2905-2919.
59. Magriples U, Naftolin F, Schwartz PE, et al. High-grade endometrial carcinoma in tamoxifen-treated breast patients. J Clin Oncol 1993; 11:485-490.
60. Miller J, Chan BKS, Nelson HD, et al. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136:680-690.
61. Cummings SR, Eckert S, Kruger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999; 281:2189-2197.
62. Burrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355:125-137.
63. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006; 295:2727-2741.
64. Rosati RI, Da Silva Jardine P, Cameron KO, et al. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 1998; 41:2928-2931.
65. Gennari L. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs Today (Barc) 2006; 42:355-367.
66. Fawell SE, White R, Hoare S, et al. Inhibition of estrogen receptor-DNA binding by the 'pure' antiestrogen ICI 164384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A 1990; 87:6883-6887.
67. Dauvois S, White R, Parker MG, et al. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993; 106:1377-1388.
68. Wakeling AE, Bowler J. Novel antiestrogens without partial agonist activity. J Steroid Biochem 1988; 31:645-653.
69. Howell A. Preliminary experience with pure antiestrogens. Clin Cancer Res 2001; 7:4369s-4375s.
70. Howell BA, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20:3396-3403.
71. Ingle JN, Suman VJ, Rowland KM, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: north central cancer treatment group trial N0032. J Clin Oncol 2006; 24:1052-1056.
72. Morales L, Timmerman D, Neven P. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol 2005; 16:70-74.
73. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective nonsteroidal aromatase inhibitor, on in vivo aromatization and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74:1286-1291.
74. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 2000; 18:3748-3757.
75. Dowsett M, Jones A, Johnston SR, et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995; 1:1511-1515.
76. Evans TR, Di Salle E, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992; 52:5933-5939.
77. Davies G, Martin LA, Sacks N, et al. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 2002; 13:669-678.
78. Diaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 2005; 90:2563-2570.
79. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-1311.
80. Mazhar D, Ang R, Waxman J. COX inhibitors and breast cancer. Br J Cancer 2006; 94:346-350. COX-2 expression has been found to correlate with aromatase expression in human breast cancer tissue. The role of COX-2 inhibitors in the treatment of breast cancer needs to be considered.